Leslie W. Kreis - Mar 17, 2022 Form 4 Insider Report for Lantern Pharma Inc. (LTRN)

Role: Director, 10%+ Owner
Signature: /s/ Leslie W. Kreis, Jr.
Stock symbol: LTRN
Transactions as of: Mar 17, 2022
Transactions value $: $15,341,497,913
Form type: 4
Date filed: 3/21/2022, 06:11 PM
Previous filing: Nov 8, 2021
Next filing: Aug 17, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LTRN	Common Stock	Exercise of in-the-money or at-the-money derivative security	$11.4B	+60.4K	+12%	$189,152.16^*	564K	Mar 17, 2022	Bios Fund I, LP	F1, F2, F3, F5
transaction	LTRN	Common Stock	Exercise of in-the-money or at-the-money derivative security	$3.91B	+35.3K	+12%	$110,636.11^*	330K	Mar 17, 2022	Bios Fund I QP, LP	F1, F2, F4, F5
holding	LTRN	Common Stock						205K	Mar 17, 2022	Bios Fund II, LP	F1, F2, F5
holding	LTRN	Common Stock						669K	Mar 17, 2022	Bios Fund II QP, LP	F1, F2, F5
holding	LTRN	Common Stock						89.5K	Mar 17, 2022	Bios Fund II NT, LP	F1, F2, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LTRN	Series A Warrants	Exercise of in-the-money or at-the-money derivative security		-60.4K	-100%		0	Mar 17, 2022	Common Stock	60.4K		Bios Fund I, LP	F1, F2, F3, F5
transaction	LTRN	Series A Warrants	Exercise of in-the-money or at-the-money derivative security		-35.3K	-100%		0	Mar 17, 2022	Common Stock	35.3K		Bios Fund I QP, LP	F1, F2, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II NT, LP ("Bios Fund II NT"). Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Mr. Kreis, and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management.
F2	Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
F3	Bios Fund I exercised warrants to purchase 60,432 shares of common stock at an exercise price of $3.13 per share.
F4	Bios Fund I QP exercised warrants to purchase 35,347 shares of common stock at an exercise price of $3.13 per share.
F5	For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.